UC TUR.WAR.OP.END. LLY/ DE000HD6P756 /
2024-08-12 8:01:27 AM | Chg.-0.040 | Bid8:34:54 AM | Ask8:34:54 AM | Underlying | Strike price | Expiration date | Option type |
---|---|---|---|---|---|---|---|
14.960EUR | -0.27% | 14.610 Bid Size: 400 |
15.550 Ask Size: 400 |
ELI LILLY | 727.9398 - | 2078-12-31 | Call |
GlobeNewswire
07-01
Ovid Therapeutics and Graviton Bioscience Announce Topline Data from a Phase 1 Clinical Trial Studyi...
GlobeNewswire
06-28
Atossa Therapeutics Announces Updated Protocol for Clinical Trial Evaluating (Z)-Endoxifen in Combin...
GlobeNewswire
06-21
HUTCHMED Announces European Commission Approval for FRUZAQLA® (fruquintinib) Received by Takeda
GlobeNewswire
06-19
Jasper Therapeutics Announces Appointment of Svetlana Lucas Ph.D., to its Board of Directors
GlobeNewswire
06-12
US Gastroenterologists Express Anticipation for Approval of AbbVie’s Skyrizi in Ulcerative Colitis, ...
GlobeNewswire
06-11
Global Multiple Sclerosis Drugs Market Size Projected to Reach $38 Billion By 2032 as Demand on R&D ...
GlobeNewswire
06-11
Skyhawk Therapeutics Promotes Clint Musil to Chief Executive Officer and Appoints Co-founder Bill Ha...
GlobeNewswire
06-11
Adverum Biotechnologies Announces Appointments of Dr. Rabia Gurses Ozden as Chief Medical Officer an...
GlobeNewswire
06-11
Biora Therapeutics Announces Presentation on the BioJet™ Systemic Oral Delivery Platform at the Next...
GlobeNewswire
06-10
Sermonix Pharmaceuticals Announces Breast Cancer Research Publication of Paper Examining Lasofoxifen...